This observational study reviewed the relationship between testosterone replacement therapy (TRT) and prostate cancer risk, concluding that while TRT restores androgen levels in hypogonadal men, it does not increase prostate cancer risk beyond that of the general population. Men with androgen deficiency typically have reduced prostate volume and lower PSA
